Singapore, April 24 -- South Korea-based Lotte Biologicshas signed a manufacturing agreement with anAsia-based biotech company for the production of a clinical-stage antibody drug conjugate (ADC) candidate.

This contract marks the first official step in the full-scale operation of the ADC manufacturing facility at the Syracuse Bio Campus inNew York, US, which has been under expansion since 2023.

With this, the company is launching its ADC contract development and manufacturing (CDMO) services, designed to meet a wide range of client needs from clinical development to commercial production. It also aims to further enhance the competitiveness of the Syracuse Bio Campus.

Building on this order, the company plans to pursue additional clien...